VYNE Therapeutics Inc (VYNE) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of vynetherapeutics.com (VYNE)

VYNE Therapeutics possesses significant pricing power in the dermatology sector by creating unique agents that block inflammation at the genetic level. This price chart shows that the EV/EBITDA ratio is 0.00. Stable management is efficiently allocating capital, moving developments into final testing phases. Business growth is driven by the success of the VYN201 drug and the development of local drug delivery systems.

VYNE Therapeutics, Inc. - VYNE Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 07/28/2026)

VYNE Therapeutics Inc (VYNE) - metric breakdowns and financial figures

- market price and analyst price targets:
Initial company analysis:VYNE (VYNE Therapeutics, Inc.)
Manufactured products of VYNE Therapeutics, Inc.

This ratio determines the financial stability of a business during a contraction of operating margins by comparing the total enterprise value to its earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA chart, an investor assesses the payback period of all assets while accounting for the debt load. For VYNE Therapeutics (VYNE), this metric is critical, as the company's market value depends directly on the success of BET inhibitor clinical trials and the patent protection of its drugs.

Competitor analysis for VYNE Therapeutics

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization krystalbio.com KRYS|Total Company Value to Operating Income Before Depreciation Ratio apogeetherapeutics.com (APGE)|ARQT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VCEL - EV/EBITDA Multiple|ORKA: EV/EBITDA Multiple|SMTI - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Technologies|Enterprise Value to Operating Income Before Depreciation SLSN (solesence.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Journey Medical (DERM)|FBRX: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Empro Corporation EMPG|Sol-Gel Technologies, Ltd. (SLGL) - Company Value to EBITDA|AXIL Brands Inc - EV/EBITDA Multiple|MDCX (Medicus Pharma Ltd.) - Enterprise Value to Operating Income Before Depreciation|Verrica (VRCA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Hoth Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization biofrontera-us.com|Enterprise Value to EBITDA Ratio Sonoma Pharmaceuticals (SNOA)|Enterprise Value to EBITDA Ratio QNRX (Quoin Pharmaceuticals Ltd)|EV/EBITDA Multiple Azitra (AZTR)|EV/EBITDA Multiple DRMA (dermatarx.com)|Business Value to Operating Income Before Depreciation ELAB|RVNC: Enterprise Value to EBITDA Ratio